Exciting news for our sponsor Xeris Pharmaceutical: FDA has approved Xeris’s Gvoke pen to treat severe hypoglycemia in pediatric and adult diabetes patients over the age of two. The FDA approval was based on data from three phase 3 clinical trials showing Gvoke’s 100% and 99% success rates in treating children and adult patients, respectively, the company said. Xeris said in a release its “usability research” showed a nearly 100% success rate in administering a full dose of glucagon in a two-step administration process. Centricity Research is proud to support and contribute to improving the health of patients worldwide through clinical research.

Read the full article HERE.